BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
12 juin 2024 04h00 HE
|
AKAMPION
Favorable safety profile of resorbable breast scaffolds in one-year follow-upNo major scaffold-related complications or scaffold removals BellaSeno will initiate multicenter pivotal clinical trial...
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
11 juin 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
11 juin 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
10 juin 2024 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the positive...
Jack’s Basket and Global Down Syndrome Foundation Collaboration To Provide More Resources to Families in the US and Around the World
06 juin 2024 12h02 HE
|
Global Down Syndrome Foundation
Denver, CO and Arden Hills, Minn., June 06, 2024 (GLOBE NEWSWIRE) -- Today the Global Down Syndrome Foundation (GLOBAL) and Jack’s Basket announced a collaboration that will provide more resources...
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
06 juin 2024 11h15 HE
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
06 juin 2024 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Microbix Advances Test-Ingredient Manufacturing Capabilities
04 juin 2024 07h00 HE
|
Microbix Biosystems Inc.
MISSISSAUGA, Ontario, June 04, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has...
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
04 juin 2024 07h00 HE
|
CytoSorbents
CTSO STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
03 juin 2024 08h00 HE
|
23andMe, Inc.
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and...